AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

BACKGROUND: Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have become the standard care of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), development of acquired resistance is inevitable. A secondary mutation of threonine 790 (T790M) is asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ren, Zhou, Shun, Xia, Bing, Zhang, Cui-ying, Hai, Ping, Zhe, Hong, Wang, Yan-yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950625/
https://www.ncbi.nlm.nih.gov/pubmed/27431492
http://dx.doi.org/10.1186/s12885-016-2519-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950625/
https://www.ncbi.nlm.nih.gov/pubmed/27431492
http://dx.doi.org/10.1186/s12885-016-2519-3

Ejemplares similares